Navigation Links
Study finds little decline in hepatitis C infections among injection drug users
Date:1/31/2011

[EMBARGOED FOR JAN. 31, 2011] A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection. The findings suggest that efforts to curb blood-borne transmission of these viral infections have had success but must be expanded against the highly transmissible HCV. Researchers from Johns Hopkins School of Public Health and other centers, led by Shruti H. Mehta, PhD, MPH, report the findings in the March 1 issue of The Journal of Infectious Diseases, now available online. (Please see below for a link to the embargoed study online.)

Previous data had suggested that HIV incidence among IDUs has declined. This trend is often attributed in part to harm reduction measures, including needle exchange programs and substance abuse treatment. However, these measures have not been as successful in lowering the rates of HCV incidence and prevalence. For example, HCV infection is nearly 10 times more transmissible by sharing needles than is HIV infection. Sharing a needle even once can be enough to transmit HCV.

The investigators found that new cases of HIV infection declined dramatically across four different time periods during the past 20 years, from 5.5 per 100 person-years (PY) in 1988-'89, to two per 100 PY in 1994-'95, and to zero cases in 1998 and 2005-'08. While researchers also observed reductions in new cases of HCV infection, these were not nearly as substantial: from 22 per 100 PY in 1988-'89, to 17.2 per 100 PY in 1994-'95, to 17.9 in 1998, and to 7.8 per 100 PY in 2005-'08. Overall, cases appeared to decline only among younger IDUs, who had started injecting drugs recently.

According to researchers, these data suggest that "current prevention efforts delay but do not prevent HCV at the population level and will need to be further intensified to reduce risk of HCV infection to the level of HIV.
'/>"/>

Contact: John Heys
jheys@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... June 02, 2015 SB 277 (CA ... for children to attend public or private school. SB277 ... but bypassed the Appropriations Committee (Sacramento Bee, May 11, ... contentious hearings. , “We believe that this bill ... (PBEs) more than it will (the) affect public health ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in business. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Job satisfaction is essential ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Woman of the Year ... leadership in life coaching. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Her work as a ...
Breaking Medicine News(10 mins):Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2
... Pharmacologic Data Presented at American Association for Cancer Research,s ... DENVER, April 21 Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced the presentation of final data from a ... picoplatin in patients with solid tumors. Results showed that ...
... April 21 Bio-Optronics, Inc. will enhance ... with click-through integration to Interspond,s RxPaying(TM) debit ... payment alternative which improves efficiency and increases ... points in clinical trial workflow into which ...
... Scenic ride and summer weekend fun ahead in Gladstone GLADSTONE, ... Cross is teaming up with several area groups and businesses to ... with the first annual "Da, U.P. Ride for the Red" on ... Friday, July 17, local food vendors will offer their fares. Beer ...
... clopidogrel can be prescribed to patients with acute ischaemia ... (ASA). The Institute for Quality and Efficiency in Health ... clopidogrel and ASA actually has a higher benefit for ... published on 31 March 2009, concludes that combination therapy ...
... April 21 More people are turning to ... their medical condition - tattooing. A case ... the American Association of Clinical Endocrinologists (AACE) 18th ... this new phenomenon, while urging discussion from the ...
... 21 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) fiscal ... 2009. You are invited to participate in a webcast the ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Second ... released to the public after the NYSE close on Monday, May ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 3Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 4Health News:New Research Reveals Need for Doctors to Know About Medical Tattoos 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
(Date:6/1/2015)... 1, 2015 NEOVIA ONCOLOGY Ltd. ... the development and commercialization of novel, multi-function drugs ... met with the U.S. Food and Drug Administration ... an Investigational New Drug (IND) application for its ... of the meeting, Neovia has clarified details of ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3Neovia Oncology Announces First IND Meeting 2
... Feb.5 Cytopia Limited (ASX: CYT) has successfully ... for CYT997, the company,s anticancer vascular-disrupting agent (VDA). ... study have been achieved. These were to determine ... toxicities (DLTs) for the agent when administered orally ...
... (OTCBB: ORMP.OB), a developer of alternative drug,delivery systems, ... of concept,study in South Africa of insulin suppositories, ... for two visits, with,two different formulations. , ... insulin absorption and reactive,glucose lowering effect. The suppositories ...
Cached Medicine Technology:Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 2Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 3Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 4Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... An indirect immunofluorescence antibody test ... anti-neutrophil cytoplasmic antibodies (ANCA) in human ... sera of patients with necrotizing vasculitides ... to the clinical and other laboratory ...
Medicine Products: